Clinical Trials Logo

Lentigo clinical trials

View clinical trials related to Lentigo.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06363240 Recruiting - Solar Lentigo Clinical Trials

Evaluation of Broadband Light Treatment for Solar Lentigines

Start date: March 12, 2024
Phase: N/A
Study type: Interventional

Broadband light treatment for Solar Lentigines

NCT ID: NCT06014619 Recruiting - Skin Cancer Clinical Trials

Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs

Start date: August 1, 2023
Phase:
Study type: Observational

Mohs micro-graphic surgery (Mohs) is a tissue-sparing, surgical treatment for different types of skin cancer (e.g. basal cell carcinoma, squamous cell carcinoma, lentigo maligna (melanoma). It is a procedure performed with frozen sections. Slow Mohs, a variant of micro-graphic surgery, is performed by formalin fixation and paraffin-embedded sections. Both in Mohs and Slow Mohs tumor margins are assessed to achieve complete removal. This study aims to investigate the clinical presentation and outcomes (i.e. complications and recurrence rates) in patients treated with Mohs or Slow Mohs in the dermatology department of the Maastricht University Medical Center+ in Maastricht, the Netherlands.

NCT ID: NCT05471947 Recruiting - Photoaging Clinical Trials

TCA 15% Chemical Peel for Improvement in Hand Lentigines

Start date: March 15, 2023
Phase: Phase 4
Study type: Interventional

This study will evaluate the efficacy of the a 15% trichloroacetic acid + 3% glycolic acid peel combination for treatment of lentigines on the hands. This peel combination is sold over the counter. Patients will receive 3 treatments (spaced 4 weeks).

NCT ID: NCT04395495 Recruiting - Neurofibromatosis 1 Clinical Trials

RASopathy Biorepository

Start date: June 27, 2017
Phase:
Study type: Observational [Patient Registry]

The RASopathies are a group of developmental disorders caused by genetic changes in the genes that compose the Ras/mitogen activated protein kinase (MAPK) pathway. New RASopathies are being diagnosed frequently. This pathway is essential in the regulation of the cell cycle and the determination of cell function. Thus, appropriate function of this pathway is critical to normal development. Each syndrome in this group of disorders has unique phenotypic features, but there are many overlapping features including facial features, heart defects, cutaneous abnormalities, cognitive delays, and a predisposition to malignancies. This research study proposes to collect and store human bio-specimens from patients with suspected or diagnosed RASopathies. Once obtained, blood and/or tissue samples will be processed for: metabolic function studies, biomarkers, genetic studies, and/or the establishment of immortalized cell lines. In addition, data from the medical record (including neuropsychological evaluations) and surveys will be stored to create a longitudinal database for research conducted at CCHMC or at other research institutions.

NCT ID: NCT03578315 Recruiting - Solar Lentigo Clinical Trials

Advanced Harmonic Generation Microscopy for Treatment Assessment of Cutaneous Pigmentary Disorder

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

In this study, the investigators demonstrated that in vivo THG microscopy can differentiate Solar lentigos (SL), Nevus zygomaticus(NZ) and normal skin based on the optical nature of melanin. This THG-based procedure provides a valuable tool for noninvasive determination of third-order nonlinear susceptibility of melanin within the skin. It can also provide real-time histopathology information for treatment follow-up, without performing an invasive skin biopsy.

NCT ID: NCT01249469 Recruiting - Solar Lentigines Clinical Trials

Evaluate the Lightening Effect of the Whitening Cosmetic Product BEX-2011

Start date: June 2010
Phase: N/A
Study type: Interventional

Background: Solar lentigines are a common dermatologic condition that manifest as circumscribed single or multiple brownish macules usually located on sun-exposed skin such as face, hands or forearms. An effective, safe, daily-use, homecare whitening product may alleviate the cosmetic concerns for the general population. The efficacy and safety of the previous generation BEX-2009 (Blanc Expert Spot Eraser, L'Oreal, France), a whitening cosmetic product containing ellagic acid, salicylic acid, licorice root extract, etc., has been established in Caucasian and Asian populations with facial solar lentigines. Objective: The purpose of this placebo-controlled, single-center study is 1) to evaluate the efficacy of the new generation whitening cosmetic product BEX-2011 (Ultimate Whitening Spot Eraser, L'Oreal, France) in the improvement of solar lentigines on the dorsum of hands or forearms, and 2) to evaluate the efficacy of BEX-2011 by harmonic generation microscopy to obtain information of the epidermal melanin continuum, compared to other standard tools for melanin measurement.

NCT ID: NCT01136629 Recruiting - Melasma Clinical Trials

Clinical, Histological and Biochemical Characterization of Hyperpigmented Lesion

Start date: June 2008
Phase: N/A
Study type: Observational

Hypothesis - The developments of solar lentigine and melasma are due to mutations in keratinocytes that drive the production and transfer of pigment from melanocytes to keratinocytes.